These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37055893)

  • 1. SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research.
    Souza Rocha W; Zhan P; Ferreira da Silva-Júnior E
    Curr Top Med Chem; 2023; 23(17):1625-1639. PubMed ID: 37055893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
    Alkhatib M; Salpini R; Carioti L; Ambrosio FA; D'Anna S; Duca L; Costa G; Bellocchi MC; Piermatteo L; Artese A; Santoro MM; Alcaro S; Svicher V; Ceccherini-Silberstein F
    Microbiol Spectr; 2022 Apr; 10(2):e0273221. PubMed ID: 35352942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
    Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
    Front Immunol; 2022; 13():871874. PubMed ID: 35898497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.
    Bharathi M; Sivamaruthi BS; Kesika P; Thangaleela S; Chaiyasut C
    Mar Drugs; 2022 Feb; 20(2):. PubMed ID: 35200677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
    Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2's Variants of Concern: A Brief Characterization.
    Scovino AM; Dahab EC; Vieira GF; Freire-de-Lima L; Freire-de-Lima CG; Morrot A
    Front Immunol; 2022; 13():834098. PubMed ID: 35958548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.
    Pérez-Vargas J; Worrall LJ; Olmstead AD; Ton AT; Lee J; Villanueva I; Thompson CAH; Dudek S; Ennis S; Smith JR; Shapira T; De Guzman J; Gang S; Ban F; Vuckovic M; Bielecki M; Kovacic S; Kenward C; Hong CY; Gordon DG; Levett PN; Krajden M; Leduc R; Boudreault PL; Niikura M; Paetzel M; Young RN; Cherkasov A; Strynadka NCJ; Jean F
    Emerg Microbes Infect; 2023 Dec; 12(2):2246594. PubMed ID: 37555275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility.
    Boer JC; Pan Q; Holien JK; Nguyen TB; Ascher DB; Plebanski M
    Front Immunol; 2022; 13():954435. PubMed ID: 36569921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
    Takashita E; Fujisaki S; Morita H; Nagata S; Miura H; Nagashima M; Watanabe S; Takeda M; Kawaoka Y; Hasegawa H
    Antiviral Res; 2023 Aug; 216():105671. PubMed ID: 37451629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
    Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X
    J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.
    Abduljaleel Z; Melebari S; Athar M; Dehlawi S; Udhaya Kumar S; Aziz SA; Dannoun AI; Malik SM; Thasleem J; George Priya Doss C
    Cell Signal; 2023 Sep; 109():110798. PubMed ID: 37423342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Omicron variant: Immune escape and vaccine development.
    Ao D; Lan T; He X; Liu J; Chen L; Baptista-Hon DT; Zhang K; Wei X
    MedComm (2020); 2022 Mar; 3(1):e126. PubMed ID: 35317190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein.
    Javanmardi K; Segall-Shapiro TH; Chou CW; Boutz DR; Olsen RJ; Xie X; Xia H; Shi PY; Johnson CD; Annapareddy A; Weaver S; Musser JM; Ellington AD; Finkelstein IJ; Gollihar JD
    Cell Host Microbe; 2022 Sep; 30(9):1242-1254.e6. PubMed ID: 35988543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.